All AbMole products are for research use only, cannot be used for human consumption.
For this product's availability, delivery time and price, please email [email protected] directly or click the "Inquiry Now" button below.
Codrituzumab-MMAE is an antibody-drug conjugate (ADC). Codrituzumab is a monoclonal antibody targeting GPC3 (glypican-3). Codrituzumab induces antibody-dependent cellular cytotoxicity (ADCC) and inhibits tumor growth.
| Form | Solution |
| Storage | Store at ≤ -20℃ for up to 24 months. Avoid repeated freeze-thaw cycles. |
| Related Antibody-Drug Conjugates (ADCs) Products |
|---|
| Vandortuzumab vedotin
Vandortuzumab vedotin (DSTP 3086S) is an antibody-drug-conjugate to target prostate cancer. |
| Enfortumab vedotin-ejfv
Enfortumab vedotin-ejfv is an anti-Nectin-4 antibody-drug conjugate (ADC) for the management of urothelial carcinoma. Enfortumab vedotin-ejfv is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE via a protease-cleavable maleimidocaproylvaline-citrulline linker. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
